2-Chloro-3-Morpholino-1,4-Naphthoquinone

2-Chloro-3-Morpholino-1,4-Naphthoquinone

SCHEMBL197256

O=C1C(Cl)=C(N2CCOCC2)C(=O)c2ccccc21

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 6/20 0.67
TDP2 O95551 5/20 0.67
ATG4B Q9Y4P1 2/20 0.67
PLA2G1B P04054 1/20 0.67
MAPT P10636 12/20 0.58
APAF1 O14727 7/20 0.58
KMT2A Q03164 5/20 0.58
POLB P06746 5/20 0.58
HKDC1 Q2TB90 4/20 0.58
GALK1 P51570 3/20 0.58
CASP3 P42574 3/20 0.58
SENP8 Q96LD8 3/20 0.58
SENP7 Q9BQF6 3/20 0.58
SENP6 Q9GZR1 3/20 0.58
RECQL P46063 2/20 0.58
THRB P10828 2/20 0.58
SAE1 Q9UBE0 1/20 0.58
UBA2 Q9UBT2 1/20 0.58
ALDH1A1 P00352 8/20 0.57
SMN1; SMN2 Q16637 6/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Chloro-3-Morpholino-1,4-Naphthoquinone SCHEMBL29590404 1.00 NSD2 (0.67) NSD2TDP2ATG4BPLA2G1BMAPT
SCHEMBL10446509 0.88 TDP2 (0.73) NSD2TDP2ATG4BPLA2G1BMAPT
SCHEMBL8568869 0.84 NSD2 (0.73) NSD2TDP2ATG4BPLA2G1BMAPT
SCHEMBL17249912 0.83 NSD2 (0.71) NSD2TDP2ATG4BPLA2G1BMAPT
SCHEMBL10446114 0.83 NSD2 (0.71) NSD2TDP2ATG4BPLA2G1BMAPT
SCHEMBL21467803 0.82 RAD51 (0.53) MAPTKMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL8651868 0.80 NSD2 (1.00) NSD2TDP2ATG4BPLA2G1BMAPT
SCHEMBL10556652 0.80 NSD2 (0.67) NSD2TDP2ATG4BPLA2G1BMAPT
SCHEMBL28689777 0.80 TDP2 (0.63) NSD2TDP2ATG4BPLA2G1BMAPT
SCHEMBL16784068 0.78 GAA (0.53) MAPTKMT2APOLBCASP3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931345-A2 METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS National Jewish Medical and Research Center (US) 2008-06-18 EP claimed
WO-2007024741-A2 METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) 2007-03-01 WO claimed
US-20060058245-A1 Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) 2006-03-16 US claimed
US-20040087527-A1 Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract NATIONAL JEWISH MEDICAL AND RESEARCH CENTER 2004-05-06 US claimed
US-4324852-A REDOX COUPLES EASTMAN KODAK COMPANY (US) 1982-04-13 US claimed
US-4201588-A NONSILVER PHOTOGRAPHIC FILMS; DISULFIDE, DIAZOANTHRONE, DIAZOPHENANTHRONE, AROMATIC AZIDE, CARBAZIDES OR QUINONES AS PHOTOREDUCTANT; EXTERNAL HYDROGEN SOURCE EASTMAN KODAK COMPANY (US) 1980-05-06 US claimed
US-4195998-A NONSILVER PHOTOGRAPHIC FILMS; DISULFIDE, DIAZOANTHRONE, DIAZOPHENANTHRONE, AROMATIC AZIDE, QUINONE OR CARBAZIDE PHOTOREDUCTANT EASTMAN KODAK COMPANY (US) 1980-04-01 US claimed
CN-110003271-B Process for producing aromatic compound 住友化学株式会社 2022-05-03 CN disclosed
US-11045796-B2 Process for producing aromatic compound, and palladium complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-06-29 US disclosed
CN-108368142-B Method for producing aromatic compound and palladium complex 住友化学株式会社 2021-02-19 CN disclosed
CN-110003271-A The preparation method of aromatic compound 住友化学株式会社 2019-07-12 CN disclosed
US-20180369799-A1 PROCESS FOR PRODUCING AROMATIC COMPOUND, AND PALLADIUM COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-12-27 US disclosed
EP-3385270-A1 METHOD FOR PRODUCING AROMATIC COMPOUND, AND PALLADIUM COMPLEX Sumitomo Chemical Company, Ltd (JP) 2018-10-10 EP disclosed
US-5658501-A Substituted naphthopyrans TRANSITIONS OPTICAL, INC. (US) 1997-08-19 US disclosed
EP-0383536-A2 Thermo-sensitive transfer printing medium SEIKO INSTRUMENTS INC. (JP) 1990-08-22 EP disclosed
US-4332884-A USING A DIOXIME CHELATING AGENT RICOH CO., LTD. (JP) 1982-06-01 US disclosed
US-4315068-A CONTAINING A COBALT-AMMINE COMPLEX AND A DIOXIME OR A BISIMIDAZOLIN-3-ONE CHELATING AGENT; STABILITY; COLOR DILMS RICOH CO., LTD. (JP) 1982-02-09 US disclosed
US-4306014-A AMMONIA OR AMINES SUPPRESS THE COLOR-FORMING REACTION SYSTEM RICOH CO., LTD. (JP) 1981-12-15 US disclosed
US-4201588-A NONSILVER PHOTOGRAPHIC FILMS; DISULFIDE, DIAZOANTHRONE, DIAZOPHENANTHRONE, AROMATIC AZIDE, CARBAZIDES OR QUINONES AS PHOTOREDUCTANT; EXTERNAL HYDROGEN SOURCE EASTMAN KODAK COMPANY (US) 1980-05-06 US disclosed
US-4171221-A NONSILVER PHOTOGTAPHY EASTMAN KODAK COMPANY (US) 1979-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087527-A1 Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract ABCC1, CFTR, ABCC2 NSD2 4702/4885TDP2 3563/4885ATG4B 1436/4885
US-11045796-B2 Process for producing aromatic compound, and palladium complex DDT, DRD1, DRD2 NSD2 702/4885TDP2 3970/4885ATG4B 770/4885
US-20060058245-A1 Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease ABCC2, CFTR, ABCC1 NSD2 4765/4885TDP2 1022/4885ATG4B 1670/4885
US-20180369799-A1 PROCESS FOR PRODUCING AROMATIC COMPOUND, AND PALLADIUM COMPLEX DDT, DRD1, DRD2 NSD2 702/4885TDP2 3970/4885ATG4B 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.